Adicet Bio (ACET) Stock Price, News & Analysis

Company Overview

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: $0.86 to $0.91
• 50-Day Range: $0.86 to $1.52
• 52-Week Range: $0.81 to $3.77
• Volume: 496,355 shs
• Average Volume: 1.06 million shs
• Market Capitalization: $74.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Moderate Buy

Adicet Bio Stock Analysis - MarketRank™

Adicet Bio scored higher than 57% of companies evaluated by MarketBeat, and ranked 501st out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Adicet Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Adicet Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adicet Bio are expected to decrease in the coming year, from ($1.39) to ($1.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adicet Bio is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adicet Bio is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adicet Bio has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.07% of the outstanding shares of Adicet Bio have been sold short.

Short Interest Ratio / Days to Cover

Adicet Bio has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in Adicet Bio has recently increased by 12.04%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Adicet Bio does not currently pay a dividend.

Dividend Growth

Adicet Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.07% of the outstanding shares of Adicet Bio have been sold short.

Short Interest Ratio / Days to Cover

Adicet Bio has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in Adicet Bio has recently increased by 12.04%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.09

News Sentiment

Adicet Bio has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Adicet Bio this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for ACET on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

4 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adicet Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.10% of the stock of Adicet Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

83.89% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACET Stock Analysis - Frequently Asked Questions

How have ACET shares performed this year?

Adicet Bio's stock was trading at $1.89 at the start of the year. Since then, ACET stock has decreased by 52.4% and is now trading at $0.90.
View the best growth stocks for 2024 here.

How were Adicet Bio's earnings last quarter?

Adicet Bio, Inc. (NASDAQ:ACET) announced its earnings results on Wednesday, November, 6th. The company reported ($0.34) EPS for the quarter, hitting analysts' consensus estimates of ($0.34).

How do I buy shares of Adicet Bio?

Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Adicet Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adicet Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 12/30/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Trading Companies & Distributors
• Current Symbol: NASDAQ:ACET
• CUSIP: 00444610
• CIK: 2034
• Web: www.aceto.com
• Phone: (650) 503-9095
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.50
• High Stock Price Target: $10.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +733.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-142,660,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -53.85%
• Return on Assets: -46.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.64
• Quick Ratio: 10.64

Sales & Book Value

• Annual Sales: $24.99 million
• Price / Sales: 2.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.43 per share
• Price / Book: 0.37

Miscellaneous

• Outstanding Shares: 82,401,000
• Free Float: 66,662,000
• Market Cap: $74.16 million
• Optionable: Optionable
• Beta: 1.88